OBJECTIVE: To assess the time course of brain atrophy and the difference across clinical subtypes in multiple sclerosis (MS). METHODS: The percent brain volume change (PBVC) was computed on existing longitudinal (2 time points) T1-weighted MRI from untreated (trial and nontrial) patients with MS. Patients (n = 963) were classified as clinically isolated syndromes suggestive of MS (CIS, 16%), relapsing-remitting (RR, 60%), secondary progressive (SP, 15%), and primary progressive (9%) MS. The median length of follow-up was 14 months (range 12-68). RESULTS: There was marked heterogeneity of the annualized PBVC (PBVC/y) across MS subtypes (p = 0.003), with higher PBVC/y in SP than in CIS (p = 0.003). However, this heterogeneity disappeared when data were corrected for the baseline normalized brain volume. When the MS population was divided into trial and nontrial subjects, the heterogeneity of PBVC/y across MS subtypes was present only in the second group, due to the higher PBVC/y values found in trial data in CIS (p = 0.01) and RR (p < 0.001). The estimation of the sample sizes required for demonstrating a reduction of brain atrophy in patients in a placebo-controlled trial showed that this was larger in patients with early MS than in those with the progressive forms of the disease. CONCLUSIONS: This first large study in untreated patients with multiple sclerosis (MS) with different disease subtypes shows that brain atrophy proceeds relentlessly throughout the course of MS, with a rate that seems largely independent of the MS subtype, when adjusting for baseline brain volume.
OBJECTIVE: To assess the time course of brain atrophy and the difference across clinical subtypes in multiple sclerosis (MS). METHODS: The percent brain volume change (PBVC) was computed on existing longitudinal (2 time points) T1-weighted MRI from untreated (trial and nontrial) patients with MS. Patients (n = 963) were classified as clinically isolated syndromes suggestive of MS (CIS, 16%), relapsing-remitting (RR, 60%), secondary progressive (SP, 15%), and primary progressive (9%) MS. The median length of follow-up was 14 months (range 12-68). RESULTS: There was marked heterogeneity of the annualized PBVC (PBVC/y) across MS subtypes (p = 0.003), with higher PBVC/y in SP than in CIS (p = 0.003). However, this heterogeneity disappeared when data were corrected for the baseline normalized brain volume. When the MS population was divided into trial and nontrial subjects, the heterogeneity of PBVC/y across MS subtypes was present only in the second group, due to the higher PBVC/y values found in trial data in CIS (p = 0.01) and RR (p < 0.001). The estimation of the sample sizes required for demonstrating a reduction of brain atrophy in patients in a placebo-controlled trial showed that this was larger in patients with early MS than in those with the progressive forms of the disease. CONCLUSIONS: This first large study in untreated patients with multiple sclerosis (MS) with different disease subtypes shows that brain atrophy proceeds relentlessly throughout the course of MS, with a rate that seems largely independent of the MS subtype, when adjusting for baseline brain volume.
Authors: Maria Pia Amato; E Portaccio; B Goretti; V Zipoli; B Hakiki; M Giannini; L Pastò; L Razzolini Journal: Neurol Sci Date: 2010-11 Impact factor: 3.307
Authors: Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman Journal: Nat Rev Neurol Date: 2015-09-15 Impact factor: 42.937
Authors: Christian Enzinger; Frederik Barkhof; Olga Ciccarelli; Massimo Filippi; Ludwig Kappos; Maria A Rocca; Stefan Ropele; Àlex Rovira; Torben Schneider; Nicola de Stefano; Hugo Vrenken; Claudia Wheeler-Kingshott; Jens Wuerfel; Franz Fazekas Journal: Nat Rev Neurol Date: 2015-11-03 Impact factor: 42.937
Authors: B Mark Keegan; Timothy J Kaufmann; Brian G Weinshenker; Orhun H Kantarci; William F Schmalstieg; M Mateo Paz Soldan; Eoin P Flanagan Journal: Neurology Date: 2016-09-16 Impact factor: 9.910
Authors: Bruce D Trapp; Megan Vignos; Jessica Dudman; Ansi Chang; Elizabeth Fisher; Susan M Staugaitis; Harsha Battapady; Sverre Mork; Daniel Ontaneda; Stephen E Jones; Robert J Fox; Jacqueline Chen; Kunio Nakamura; Richard A Rudick Journal: Lancet Neurol Date: 2018-08-22 Impact factor: 44.182
Authors: Isabela T Borges; Colin D Shea; Joan Ohayon; Blake C Jones; Roger D Stone; John Ostuni; Navid Shiee; Henry McFarland; Bibiana Bielekova; Daniel S Reich Journal: Mult Scler Relat Disord Date: 2013-04-01 Impact factor: 4.339